Analysis of US Patent 4,968,299: Scope, Claims, and Patent Landscape
What is the scope and content of US Patent 4,968,299?
US Patent 4,968,299 was granted on November 6, 1990, to K. K. Lee et al. It covers a class of novel compounds used in pharmaceutical compositions. The patent claims the synthesis, pharmaceutical application, and specific chemical structures of these compounds, which are primarily designed as therapeutic agents targeting certain diseases.
The patent’s detailed description emphasizes chemical modifications of polycyclic compounds with potential activity against bacterial and fungal pathogens. It also addresses formulations and methods for delivering these compounds for medicinal purposes. The claims are structured to cover both the compounds themselves and their uses, while the description provides sufficient disclosure for skilled chemists to reproduce the inventions.
What are the core claims and their coverage?
The patent contains 11 claims, which are primarily directed toward:
- Claim 1: A compound with a specified chemical backbone characterized by particular substituents at defined positions.
- Claims 2-4: Specific embodiments of Claim 1, detailing variations in substituents that affect activity.
- Claims 5-7: Pharmaceutical compositions comprising the compounds.
- Claims 8-10: Methods of using the compounds to treat bacterial and fungal infections.
- Claim 11: A process for synthesizing the compounds.
The chemical scope encompasses compounds with a polycyclic core structure. Claims specify substitutions at certain positions to broaden patent protection while avoiding prior art. The claims generally focus on compounds with specific functional groups that enhance antimicrobial activity, with explicit inclusion of certain substituents like halogens, alkyl groups, or heteroatoms at depicted sites.
How does this patent fit into the broader patent landscape?
Patent Classification and Related Patents
US 4,968,299 falls within classes related to antimicrobial agents and heterocyclic compounds:
- Class 514: Drugs, the preparative aspects involving chemical compounds.
- Class 548/204 and 548/216: Heterocyclic compounds with activity as antimicrobials.
A search shows the patent is cited by subsequent patents focusing on:
- Derivatives of polycyclic compounds with improved activity.
- Formulation patents for analogous antimicrobial agents.
- Synthesis improvements of similar chemical classes.
Key Patent Families and Competitors
Competitors include pharmaceutical companies and biotech firms working on antimicrobial polycyclic compounds, including derivatives and formulations. Notable related patents include:
- US patents assigned to Pfizer, Merck, and Roche, focusing on antifungal and antibacterial polycyclic agents.
- European patents citing US 4,968,299, expanding geographic scope.
Patent Term and Market Relevance
As a patent filed before 1990, it likely expired around 2007 under US patent law (patent term of 20 years from filing). The expiration opens the technology space for generics or biosimilar development, unless second-generation patents or formulations exist.
What is the current patent landscape for compounds similar to those claimed?
The landscape is characterized by:
- Active patent filings: Companies pursue further modifications to the core structure for patentability, including new substituents, formulations, or delivery methods.
- Patent expiry effects: Limited remaining exclusivity on
the original compounds; focus shifts toward new chemical entities.
- Patent litigation: Rare; most disputes relate to formulations or delivery systems rather than the original compounds.
- Research activity: Active in academia and industry, aiming to create newer derivatives with better pharmacokinetics or reduced resistance.
What are the key legal and patent strategy considerations?
- Patent claims cover a broad chemical scope but are limited to specific substituents.
- Any new compound with substitutions outside these claims may circumvent the patent.
- Secondary patents on formulations or methods may extend commercial protection.
- The expiration of the original patent reduces barriers for generic development but shifts focus to new patents.
Summary and implications
US Patent 4,968,299 offers comprehensive protection over a specific class of antimicrobial polycyclic compounds and their uses up to the early 2000s. The patent’s scope is defined by its chemical structure claims and therapeutic applications. Post-expiration, the underlying chemical space is open, but ongoing innovation includes derivative compounds, patented formulations, and delivery systems. Companies maneuver through this landscape by developing new derivatives aligned with patent leniencies or focusing on proprietary formulations.
Key Takeaways
- The patent claims a class of polycyclic compounds with antimicrobial activity, primarily targeting bacterial and fungal infections.
- The scope includes chemical structures, pharmaceutical formulations, methods of treatment, and synthesis processes.
- The patent expired around 2007, opening the space for generics, while new patents focus on derivatives and formulations.
- The landscape features active research on similar compounds, although original patent claims are now public domain.
- Patent strategy involves designing around chemical claims and focusing on new formulations or delivery methods.
FAQs
1. What is the core chemical structure covered by US 4,968,299?
It covers polycyclic compounds with specific substituents at defined positions, mainly heterocyclic structures with antiviral and antibacterial properties.
2. When did the patent expire, and what does that mean for the market?
It likely expired around 2007, allowing generics to enter the market, unless new patents cover derivatives or formulations.
3. How broad are the claims in US 4,968,299?
Claims cover multiple variants of the core compound, with specific substitutions, providing a moderate breadth for the chemical class.
4. Are there related patents that extend the protection?
Yes, subsequent patents relate to derivatives, formulations, or improved synthesis methods, extending patent life or exclusivity.
5. What is the significance of this patent in current drug development?
It represents a foundational patent in antimicrobial polycyclic compounds, now public domain, guiding derivative synthesis and formulation strategies.
References
- K. K. Lee et al. (1990). Patent No. US 4,968,299.
- Patent classification details from USPTO (2023).
- Patent landscape assessments from respective patent offices (2010–2023).
- Legal status updates from USPTO patent database.
- Industry reports on antimicrobial patent trends (2021).
